Analyst: This Penny Stock Could Triple

Oppenheimer is upbeat on APTO's cancer drug

Jan 25, 2019 at 10:59 AM
facebook twitter linkedin


Oppenheimer initiated coverage on Aptose Biosciences Inc (NASDAQ:APTO) with an "outperform" rating and a $6 price target -- a nearly 200% premium to last night's close -- sending the stock up 3.5% to trade at $2.09. The brokerage firm waxed optimistic on the company's cancer drug, CG-806, and its potential for commercial growth as a treatment for both acute myeloid leukemia and chronic lymphocytic leukemia.

Analysts are already bullish on APTO, with all three in coverage maintaining a "strong buy" rating. Plus, the average 12-month price target sits all the way up at $6.63 -- a level not seen by the stock since November 2015.

Short sellers, on the other hand, have actively targeted the stock, with short interest on Aptose Biosciences up 270% from its mid-June low -- and nearly 21% higher in the latest reporting period alone. However, the bearish bandwagon is far from full, considering the 740,000 APTO shares sold short represents a low 3.1% of the equity's available float.

The drug stock has certainly felt the heat from this steady stream of selling pressure, down 54% from its mid-June two-year peak of $4.55. More recently, APTO shares have been churning between support near $1.80 and resistance near $2.50 since an early September breach of their 200-day moving average, with today's upside running out of steam near the 80-day trendline.

apto stock daily price chart jan 25

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners